Triple
T4061237
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Center for Biologics Evaluation and Research |
E86214
|
entity |
| Predicate | hasDivision |
P35
|
FINISHED |
| Object |
Office of Tissues and Advanced Therapies
The Office of Tissues and Advanced Therapies is a U.S. FDA office responsible for regulating cellular and gene therapies, tissue-based products, and other advanced biologic treatments.
|
E409911
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Office of Tissues and Advanced Therapies | Statement: [Center for Biologics Evaluation and Research, hasDivision, Office of Tissues and Advanced Therapies]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Office of Tissues and Advanced Therapies Context triple: [Center for Biologics Evaluation and Research, hasDivision, Office of Tissues and Advanced Therapies]
-
A.
Human Tissue Authority
The Human Tissue Authority is a UK regulatory body responsible for licensing and overseeing the removal, storage, use, and disposal of human bodies, organs, and tissue for purposes such as research, transplantation, and education.
-
B.
Committee for Advanced Therapies
The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
-
C.
Center for Cellular and Molecular Therapeutics
The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
-
D.
NHS Blood and Transplant
NHS Blood and Transplant is a UK special health authority responsible for providing a safe and reliable supply of blood, organs, and associated services to the National Health Service.
-
E.
Office of Translational Sciences
The Office of Translational Sciences is a scientific office within the U.S. Food and Drug Administration that advances the translation of biomedical research into safe and effective drug therapies through regulatory science, research, and policy development.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Office of Tissues and Advanced Therapies Triple: [Center for Biologics Evaluation and Research, hasDivision, Office of Tissues and Advanced Therapies]
Generated description
The Office of Tissues and Advanced Therapies is a U.S. FDA office responsible for regulating cellular and gene therapies, tissue-based products, and other advanced biologic treatments.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Office of Tissues and Advanced Therapies Target entity description: The Office of Tissues and Advanced Therapies is a U.S. FDA office responsible for regulating cellular and gene therapies, tissue-based products, and other advanced biologic treatments.
-
A.
Human Tissue Authority
The Human Tissue Authority is a UK regulatory body responsible for licensing and overseeing the removal, storage, use, and disposal of human bodies, organs, and tissue for purposes such as research, transplantation, and education.
-
B.
Committee for Advanced Therapies
The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
-
C.
Center for Cellular and Molecular Therapeutics
The Center for Cellular and Molecular Therapeutics is a research institute specializing in developing gene and cell-based therapies for pediatric and genetic diseases.
-
D.
NHS Blood and Transplant
NHS Blood and Transplant is a UK special health authority responsible for providing a safe and reliable supply of blood, organs, and associated services to the National Health Service.
-
E.
Office of Translational Sciences
The Office of Translational Sciences is a scientific office within the U.S. Food and Drug Administration that advances the translation of biomedical research into safe and effective drug therapies through regulatory science, research, and policy development.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69aed93c69208190a4efac0efe3cd69b |
completed | March 9, 2026, 2:29 p.m. |
| NER | Named-entity recognition | batch_69aefbd4acb0819093bcffcd05ed8e6f |
completed | March 9, 2026, 4:56 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69b562ac25848190951431c9c853cc59 |
completed | March 14, 2026, 1:29 p.m. |
| NEDg | Description generation | batch_69b5633103e081909dbe7a7e54877343 |
completed | March 14, 2026, 1:31 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69b563eca17c81908deff0d361a7be87 |
completed | March 14, 2026, 1:34 p.m. |
Created at: March 9, 2026, 3:38 p.m.